EDITORIAL

Cancer Therapy Reform

Science  09 Apr 2010:
Vol. 328, Issue 5975, pp. 137
DOI: 10.1126/science.1189749

You are currently viewing the summary.

View Full Text

Summary

Last month, the U.S. Food and Drug Administration (FDA) announced that it plans to draft new guidelines for testing and approving the use of multidrug treatments for diseases. For cancer treatment, the need for this approach and its attendant guidelines are based on an advanced understanding of the disease that has emerged from 30 years of research. If we are to achieve breakthrough cancer therapies, current FDA regulations must change.